Premium
Neuroinflammation in Alzheimer's disease and beneficial action of luteolin
Author(s) -
Delgado Alejandro,
Cholevas Christos,
Theoharides Theoharis C.
Publication year - 2021
Publication title -
biofactors
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.204
H-Index - 94
eISSN - 1872-8081
pISSN - 0951-6433
DOI - 10.1002/biof.1714
Subject(s) - neuroinflammation , disease , pathogenesis , neuroscience , luteolin , dementia , medicine , alzheimer's disease , amyloid (mycology) , amyloid β , microglia , bioinformatics , psychology , biology , immunology , inflammation , pathology , antioxidant , quercetin , biochemistry
Abstract Alzheimer's disease (AD), already the world's most common form of dementia, is projected to continue increasing in prevalence over the next several decades. The current lack of understanding of the pathogenesis of AD has hampered the development of effective treatments. Historically, AD research has been predicated on the amyloid cascade hypothesis (ACH), which attributes disease progression to the build‐up of amyloid protein. However, multiple clinical studies of drugs interfering with ACH have failed to show any benefit demonstrating that AD etiology is more complex than previously thought. Here we review the current literature on the emerging key role of neuroinflammation, especially activation of microglia, in AD pathogenesis. Moreover, we provide compelling evidence that certain flavonoids, especially luteolin formulated in olive pomace oil together with hydroxytyrosol, offers a reasonable prophylactic treatment approach due to its many beneficial actions.